Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05085548Phase 1Completed

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

Role: lead

NCT06182072Phase 1Recruiting

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Role: lead

NCT06460298Phase 1Recruiting

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Role: lead

All 3 trials loaded